S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Can Etsy Continue to Thrive After the Pandemic?
'The Sacrifice Zone': Myanmar bears cost of green energy
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Can Etsy Continue to Thrive After the Pandemic?
'The Sacrifice Zone': Myanmar bears cost of green energy
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Can Etsy Continue to Thrive After the Pandemic?
'The Sacrifice Zone': Myanmar bears cost of green energy
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Can Etsy Continue to Thrive After the Pandemic?
'The Sacrifice Zone': Myanmar bears cost of green energy
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
NASDAQ:MDRX

Allscripts Healthcare Solutions - MDRX Stock Forecast, Price & News

$17.45
-0.08 (-0.46%)
(As of 08/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$17.29
$17.79
50-Day Range
$14.26
$17.53
52-Week Range
$13.05
$23.25
Volume
1.62 million shs
Average Volume
1.15 million shs
Market Capitalization
$2.02 billion
P/E Ratio
40.58
Dividend Yield
N/A
Price Target
$22.00

Allscripts Healthcare Solutions MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
26.1% Upside
$22.00 Price Target
Short Interest
Healthy
9.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
0.93mentions of Allscripts Healthcare Solutions in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$5.55 M Sold Last Quarter
Proj. Earnings Growth
-1.49%
From $0.67 to $0.66 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.34 out of 5 stars

Medical Sector

298th out of 1,098 stocks

Computer Integrated Systems Design Industry

10th out of 40 stocks

MDRX stock logo

About Allscripts Healthcare Solutions (NASDAQ:MDRX) Stock

Allscripts Healthcare Solutions, Inc., together with its subsidiaries, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions. The company operates through two segments, Hospitals and Large Physician Practices, and Veradigm. The Hospitals and Large Physician Practices segment provides integrated clinical and financial management solutions, which primarily include EHR-related software; and related installation, support and maintenance, outsourcing, private cloud hosting, and revenue cycle management services. The Veradigm segment offers payer and life sciences solutions, which are primarily targeted at payers, life sciences companies, and other healthcare stakeholders; and software applications for patient engagement and EHR software to single-specialty, and small and mid-sized physician practices, including related clinical, financial, administrative, and operational solutions. Its solutions enable clients to transition, analyze, and coordinate care, and enhance the healthcare delivery across the care community. The company serves physicians, hospitals, governments and militaries, health systems, health plans, life-sciences companies, retail clinics, surgery centers, retail pharmacies, pharmacy benefit managers, insurance companies, employer wellness clinics, consumers, lab companies, urgent care facilities, and venture capital firms, as well as post-acute organizations, such as home health and hospice agencies. Allscripts Healthcare Solutions, Inc. was founded in 1986 and is headquartered in Chicago, Illinois.

Allscripts Healthcare Solutions Trading Down 0.5 %

NASDAQ:MDRX opened at $17.45 on Tuesday. Allscripts Healthcare Solutions has a 1 year low of $13.05 and a 1 year high of $23.25. The company has a debt-to-equity ratio of 0.17, a quick ratio of 2.38 and a current ratio of 3.23. The stock has a market cap of $2.02 billion, a P/E ratio of 40.58, a P/E/G ratio of 1.60 and a beta of 1.02. The stock has a 50-day simple moving average of $15.58 and a 200-day simple moving average of $18.83.

Allscripts Healthcare Solutions (NASDAQ:MDRX - Get Rating) last posted its earnings results on Thursday, August 4th. The software maker reported $0.18 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.03. Allscripts Healthcare Solutions had a return on equity of 10.62% and a net margin of 5.90%. The business had revenue of $150.90 million during the quarter, compared to the consensus estimate of $148.58 million. During the same period in the previous year, the business earned $0.17 EPS. The business's quarterly revenue was up 6.9% on a year-over-year basis. As a group, analysts anticipate that Allscripts Healthcare Solutions will post 0.67 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. TheStreet downgraded Allscripts Healthcare Solutions from a "b" rating to a "c" rating in a research report on Friday, May 6th. Piper Sandler dropped their price objective on Allscripts Healthcare Solutions from $19.00 to $17.00 in a research note on Thursday, June 9th. StockNews.com cut Allscripts Healthcare Solutions from a "buy" rating to a "hold" rating in a research note on Friday, May 13th. Finally, The Goldman Sachs Group initiated coverage on Allscripts Healthcare Solutions in a research note on Tuesday, July 12th. They issued a "neutral" rating and a $21.00 price objective for the company. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $21.80.

Insider Activity

In other Allscripts Healthcare Solutions news, Director Paul Black sold 60,000 shares of the company's stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $16.58, for a total transaction of $994,800.00. Following the completion of the sale, the director now directly owns 1,254,631 shares of the company's stock, valued at approximately $20,801,781.98. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Allscripts Healthcare Solutions news, Director Paul Black sold 60,000 shares of the company's stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $16.58, for a total transaction of $994,800.00. Following the completion of the sale, the director now directly owns 1,254,631 shares of the company's stock, valued at approximately $20,801,781.98. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Elizabeth Ann Altman sold 6,028 shares of the company's stock in a transaction that occurred on Friday, May 27th. The shares were sold at an average price of $16.75, for a total value of $100,969.00. Following the sale, the director now directly owns 22,796 shares of the company's stock, valued at $381,833. The disclosure for this sale can be found here. In the last three months, insiders sold 266,478 shares of company stock valued at $4,616,204. Insiders own 2.29% of the company's stock.

Receive MDRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allscripts Healthcare Solutions and its competitors with MarketBeat's FREE daily newsletter.

MDRX Stock News Headlines

AllScripts: Q2 Earnings Snapshot
Allscripts Announces Second Quarter of 2022 Results
Analyst Ratings for Allscripts Healthcare
Allscripts Healthcare Solutions Inc. Q1 Income Climbs
See More Headlines
Receive MDRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allscripts Healthcare Solutions and its competitors with MarketBeat's FREE daily newsletter.

MDRX Company Calendar

Last Earnings
8/04/2022
Today
8/09/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Computer integrated systems design
Sub-Industry
Health Care Technology
Sector
Medical
Current Symbol
NASDAQ:MDRX
CUSIP
01988P10
Employees
8,000
Year Founded
1986

Price Target and Rating

Average Stock Price Forecast
$22.00
High Stock Price Forecast
$26.00
Low Stock Price Forecast
$17.00
Forecasted Upside/Downside
+26.1%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$134.44 million
Pretax Margin
12.42%

Debt

Sales & Book Value

Annual Sales
$1.50 billion
Cash Flow
$2.74 per share
Book Value
$11.49 per share

Miscellaneous

Free Float
113,363,000
Market Cap
$2.02 billion
Optionable
Optionable
Beta
1.02

Social Links


Key Executives

  • Mr. Richard J. Poulton (Age 57)
    CEO & Director
    Comp: $2.45M
  • Ms. Tejal Vakharia (Age 49)
    Sr. VP of Marketing & Gov. Affairs, Gen. Counsel and Chief Compliance Counsel
    Comp: $1.04M
  • Mr. Thomas J. Langan (Age 56)
    Pres & CCO
  • Ms. Leah Jones (Age 50)
    Chief Financial Officer
  • Mr. Joseph R. Rostock (Age 59)
    Sr. VP of Devel. & CTO
  • Jenny Gelinas
    VP of Investor Relations
  • Mr. Richard Elmore
    Sr. VP of Corp. Devel. & Strategy
  • Ms. Rebecca Whaley
    VP of Marketing
  • Ms. Lisa Hammond C.P.C. (Age 50)
    Sr. VP & Chief HR Officer
  • Mr. Paul Lewis
    Sr. VP of Sales & Services and Acting Gen. Mang.













MDRX Stock - Frequently Asked Questions

Should I buy or sell Allscripts Healthcare Solutions stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allscripts Healthcare Solutions in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MDRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MDRX, but not buy additional shares or sell existing shares.
View MDRX analyst ratings
or view top-rated stocks.

What is Allscripts Healthcare Solutions' stock price forecast for 2022?

5 analysts have issued 1-year price targets for Allscripts Healthcare Solutions' shares. Their MDRX share price forecasts range from $17.00 to $26.00. On average, they anticipate the company's share price to reach $22.00 in the next twelve months. This suggests a possible upside of 26.1% from the stock's current price.
View analysts price targets for MDRX
or view top-rated stocks among Wall Street analysts.

How has Allscripts Healthcare Solutions' stock price performed in 2022?

Allscripts Healthcare Solutions' stock was trading at $18.45 at the beginning of 2022. Since then, MDRX stock has decreased by 5.4% and is now trading at $17.45.
View the best growth stocks for 2022 here
.

When is Allscripts Healthcare Solutions' next earnings date?

Allscripts Healthcare Solutions is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our MDRX earnings forecast
.

How were Allscripts Healthcare Solutions' earnings last quarter?

Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) announced its quarterly earnings data on Thursday, August, 4th. The software maker reported $0.18 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.15 by $0.03. The software maker earned $150.90 million during the quarter, compared to analysts' expectations of $148.58 million. Allscripts Healthcare Solutions had a trailing twelve-month return on equity of 10.62% and a net margin of 5.90%. Allscripts Healthcare Solutions's revenue was up 6.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.17 EPS.

How will Allscripts Healthcare Solutions' stock buyback program work?

Allscripts Healthcare Solutions declared that its Board of Directors has initiated a stock buyback plan on Wednesday, May 26th 2021, which allows the company to repurchase $350,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to buy up to 14% of its stock through open market purchases. Stock repurchase plans are often an indication that the company's board believes its stock is undervalued.

What guidance has Allscripts Healthcare Solutions issued on next quarter's earnings?

Allscripts Healthcare Solutions issued an update on its FY 2022 earnings guidance on Monday, May, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.52 billion-$1.53 billion, compared to the consensus revenue estimate of $1.53 billion.

What is Paul Black's approval rating as Allscripts Healthcare Solutions' CEO?

796 employees have rated Allscripts Healthcare Solutions Chief Executive Officer Paul Black on Glassdoor.com. Paul Black has an approval rating of 65% among the company's employees.

What other stocks do shareholders of Allscripts Healthcare Solutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allscripts Healthcare Solutions investors own include Advanced Micro Devices (AMD), Netflix (NFLX), Energy Transfer (ET), CVS Health (CVS), Ford Motor (F), Himax Technologies (HIMX), Intel (INTC), OPKO Health (OPK), Tesla (TSLA) and Activision Blizzard (ATVI).

What is Allscripts Healthcare Solutions' stock symbol?

Allscripts Healthcare Solutions trades on the NASDAQ under the ticker symbol "MDRX."

Who are Allscripts Healthcare Solutions' major shareholders?

Allscripts Healthcare Solutions' stock is owned by many different institutional and retail investors. Top institutional shareholders include Loomis Sayles & Co. L P (1.32%), Fort Washington Investment Advisors Inc. OH (0.69%), Smith Graham & Co. Investment Advisors LP (0.48%), SG Americas Securities LLC (0.32%), Cambria Investment Management L.P. (0.19%) and New York State Teachers Retirement System (0.19%). Insiders that own company stock include Brian Farley, Dennis Olis, Elaina Shekhter, Elizabeth Ann Altman, Greg Garrison, Lisa Khorey, Michael Klayko, Paul Black, Richard J Poulton and Thomas Langan.
View institutional ownership trends
.

How do I buy shares of Allscripts Healthcare Solutions?

Shares of MDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allscripts Healthcare Solutions' stock price today?

One share of MDRX stock can currently be purchased for approximately $17.45.

How much money does Allscripts Healthcare Solutions make?

Allscripts Healthcare Solutions (NASDAQ:MDRX) has a market capitalization of $2.02 billion and generates $1.50 billion in revenue each year. The software maker earns $134.44 million in net income (profit) each year or $0.43 on an earnings per share basis.

How many employees does Allscripts Healthcare Solutions have?

Allscripts Healthcare Solutions employs 8,000 workers across the globe.

Does Allscripts Healthcare Solutions have any subsidiaries?

The following companies are subsidiares of Allscripts Healthcare Solutions: HealthGrid, Practice Fusion, and ZappRx.
Read More

When was Allscripts Healthcare Solutions founded?

Allscripts Healthcare Solutions was founded in 1986.

How can I contact Allscripts Healthcare Solutions?

Allscripts Healthcare Solutions' mailing address is 222 MERCHANDISE MART PLAZA SUITE 2024, CHICAGO IL, 60654. The official website for the company is www.allscripts.com. The software maker can be reached via phone at (800) 334-8534, via email at stephen.shulstein@allscripts.com, or via fax at 313-322-9600.

This page (NASDAQ:MDRX) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.